DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Wilhelm SM, Dumas J, Adnane L et al.
Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.
Int J Cancer 2011;
129: 245-255
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.